NOVELLI, Francesco
 Distribuzione geografica
Continente #
NA - Nord America 9419
EU - Europa 7105
AS - Asia 3929
AF - Africa 181
OC - Oceania 83
SA - Sud America 51
Continente sconosciuto - Info sul continente non disponibili 29
Totale 20797
Nazione #
US - Stati Uniti d'America 9277
CN - Cina 2630
IT - Italia 1599
SE - Svezia 958
DE - Germania 818
DK - Danimarca 716
UA - Ucraina 640
FR - Francia 572
FI - Finlandia 440
AT - Austria 400
KR - Corea 373
TW - Taiwan 312
PL - Polonia 301
GB - Regno Unito 290
VN - Vietnam 191
SN - Senegal 160
JP - Giappone 138
CA - Canada 110
AU - Australia 79
NL - Olanda 69
TR - Turchia 67
IN - India 66
ES - Italia 49
BE - Belgio 40
GR - Grecia 39
RU - Federazione Russa 37
HK - Hong Kong 33
BR - Brasile 29
CH - Svizzera 28
MX - Messico 28
EU - Europa 26
SG - Singapore 20
IL - Israele 17
NO - Norvegia 17
UZ - Uzbekistan 17
RO - Romania 14
BY - Bielorussia 12
HU - Ungheria 11
EE - Estonia 9
PT - Portogallo 9
ID - Indonesia 8
MU - Mauritius 8
TH - Thailandia 8
AE - Emirati Arabi Uniti 7
CZ - Repubblica Ceca 7
IR - Iran 7
SA - Arabia Saudita 7
IE - Irlanda 6
AL - Albania 5
LB - Libano 5
MO - Macao, regione amministrativa speciale della Cina 5
PE - Perù 5
PH - Filippine 5
AR - Argentina 4
BG - Bulgaria 4
CO - Colombia 4
EG - Egitto 4
LU - Lussemburgo 4
NZ - Nuova Zelanda 4
CL - Cile 3
MD - Moldavia 3
MY - Malesia 3
PK - Pakistan 3
A1 - ???statistics.table.value.countryCode.A1??? 2
BN - Brunei Darussalam 2
DZ - Algeria 2
EC - Ecuador 2
KE - Kenya 2
PR - Porto Rico 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
UY - Uruguay 2
VE - Venezuela 2
AP - ???statistics.table.value.countryCode.AP??? 1
BA - Bosnia-Erzegovina 1
BD - Bangladesh 1
BZ - Belize 1
CU - Cuba 1
CY - Cipro 1
GH - Ghana 1
HR - Croazia 1
IQ - Iraq 1
LK - Sri Lanka 1
MK - Macedonia 1
RS - Serbia 1
SC - Seychelles 1
SY - Repubblica araba siriana 1
ZA - Sudafrica 1
Totale 20797
Città #
Beijing 1252
Ann Arbor 1205
Houston 719
Chandler 672
Fairfield 641
Wilmington 526
Dearborn 452
Torino 431
Jacksonville 421
Vienna 396
Woodbridge 351
Villeurbanne 350
Princeton 291
Medford 283
Ashburn 272
Warsaw 272
Taipei 251
Fremont 241
Guangzhou 241
Redwood City 241
Cambridge 240
Seattle 222
Pisa 183
Shanghai 148
Dong Ket 132
Boston 103
Nyköping 99
Milan 89
Nanjing 87
Wuhan 77
Hangzhou 60
San Diego 57
Turin 55
Chengdu 50
Rome 50
Norwalk 48
Shenyang 48
San Mateo 42
Toronto 38
Zhengzhou 38
Falls Church 37
Xian 37
Jinan 34
Kunming 34
Mountain View 34
Verona 33
Hefei 32
Düsseldorf 31
Tokyo 31
Changsha 28
Changchun 27
Brussels 26
Munich 26
Phoenix 26
Seoul 25
Hebei 24
Chongqing 21
Nanchang 21
Heidelberg 20
Ottawa 19
Villadose 18
Melbourne 17
Menlo Park 17
Lachine 16
Lanzhou 16
Los Angeles 16
Polska 16
Wayne 16
Detroit 15
Fuzhou 15
London 15
Nürnberg 15
Silver Spring 15
Farmington 14
Kharkiv 14
Paris 14
Montréal 13
Piemonte 13
Central District 12
Dallas 12
New York 12
Pittsburgh 12
Naples 11
Rochester 11
Erlangen 10
Genova 10
Leawood 10
Napoli 10
Stavanger 10
Lyon 9
Nanning 9
Oxford 9
Redmond 9
Absecon 8
Bethesda 8
Guiyang 8
Harbin 8
Lincoln 8
Baotou 7
Birmingham 7
Totale 12425
Nome #
Alpha-Enolase (ENO1), a potential target in novel immunotherapies 1200
Class II Transactivator-Induced MHC Class II Expression in Pancreatic Cancer Cells Leads to Tumor Rejection and a Specific Antitumor Memory Response. 394
Pregnancy epigenetic signature in T helper 17 and T regulatory cells in multiple sclerosis 339
Circulating Autoantibodies to Phosphorylated α-Enolase are a Hallmark of Pancreatic Cancer. 337
A bioluminescent mouse model of proliferation to highlight early stages of pancreatic cancer: A suitable tool for preclinical studies 326
Vaccination with ENO1 DNA Prolongs Survival of Genetically Engineered Mice with Pancreatic Cancer. 324
Molecular and genetic bases of pancreatic cancer 315
Integrative Analysis of Novel Metabolic Subtypes in Pancreatic Cancer Fosters New Prognostic Biomarkers 293
Regulation of Langerhans cell functions in a hypoxic environment 285
Overcoming the Lack of Kinetic Information in Biochemical Reactions Networks 249
Dealing with indetermination in biochemical networks 241
Phosphorylated alpha-enolase induces autoantibodies in HLA-DR8 pancreatic cancer patients and triggers HLA-DR8 restricted T-cell activation. 234
Phosphoinositide 3-Kinase Gamma Inhibition Protects from Anthracycline Cardiotoxicity and Reduces Tumor Growth 224
Alpha-enolase (ENO1) controls alpha v/beta 3 integrin expression and regulates pancreatic cancer adhesion, invasion, and metastasis 222
The advanced glycation end-product Nϵ-carboxymethyllysine promotes progression of pancreatic cancer: implications for diabetes-associated risk and its prevention 216
The ATP-binding cassette transporter A1 regulates phosphoantigen release and Vγ9Vδ2 T cell activation by dendritic cells 212
Hypoxia modulates the gene expression profile of immunoregulatory receptors in human mDCs: identification of TREM-1 as a novel hypoxic marker in vitro and in vivo. 212
CC-chemokine ligand 16 induces a novel maturation program in human immature monocyte-derived dendritic cells 210
Mouse hepatocytes and LSEC proteome reveal novel mechanisms of ischemia/reperfusion damage and protection by A2a receptor stimulation 203
Pancreatic cancer vaccine: a unique potential therapy 197
Immune-Complexome Analysis Identifies Immunoglobulin-Bound Biomarkers That Predict the Response to Chemotherapy of Pancreatic Cancer Patients 191
Chemotherapy effects on immune-complexes in pancreatic ductal adenocarcinoma patients serum 189
Targeting the Warburg effect in cancer cells through ENO1 knockdown rescues oxidative phosphorylation and induces growth arrest 183
FAM49B, a novel regulator of mitochondrial function and integrity that suppresses tumor metastasis 182
Proteomic data analysis of pancreatic cancer patient sera revealed how chemotherapy shapes the immunogenicity of developing tumors 177
Targeting of surface alpha-enolase inhibits the invasiveness of pancreatic cancer cells 174
Macrophage PI3Kγ drives pancreatic ductal adenocarcinoma progression 170
Inspecting Energy Releasing Pathways by combination of genomics data and mechanistic approach. 168
Peripheral ENO1-specific T cells mirror the intratumoral immune response and their presence is a potential prognostic factor for pancreatic adenocarcinoma 167
null 167
Inspecting Energy Releasing Pathways by combination of genomics data and mechanistic approach. 165
Regulation of Human Macrophage M1-M2 Polarization Balance by Hypoxia and the Triggering Receptor Expressed on Myeloid Cells-1. 165
α-enolase: a promising therapeutic and diagnostic tumor target 164
Anti-α-enolase antibody limits the invasion of myeloid-derived suppressor cells and attenuates their restraining effector T cell response 161
Computational modeling of pancreatic cancer cells metabolism 159
Beta-2-glycoprotein-1 and alpha-1-antitrypsin as urinary markers of renal cancer in von Hippel–Lindau patients 153
Depletion of tumor-associated macrophages switches the epigenetic profile of pancreatic cancer infiltrating T cells and restores their anti-tumor phenotype 149
Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months 144
Cancer and chemotherapy contribute to muscle loss by activating common signaling pathways 144
Inspecting energy releasing pathways by a combination of genomics data and mechanistic approach 141
Oxidative stress-mediated antimalarial activity of plakortin, a natural endoperoxide from the tropical sponge Plakortis simplex 138
STAT1 and STAT3 in Tumorigenesis: Two Sides of the Same Coin? 135
Next generation immunotherapy for pancreatic cancer: DNA vaccination is seeking new combo partners 135
Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models. 132
Alemtuzumab Long Term Immunological Study: The Immunosuppressive Effect Does Not Last More Than 48 Months 130
Chimeric Rat/Human HER2 Efficiently Circumvents HER2 Tolerance in Cancer Patients. 129
Proteomic analysis of extracellular vesicles from medullospheres reveals a role for iron in the cancer progression of medulloblastoma 122
Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma 118
In Human Multiple sclerosis, T helper 17 lymphocytes display increased levels of JAK2 that stabilize cell surface IFN-YR2chain 117
T helper subsets changes in alemtuzumab multiple sclerosis treated patients: the recovery of immune system capacity as a possible indicator to treatment 117
BLOCKADE OF SURFACE ALPHA-ENOLASE (ENO1) AS A NOVEL IMMUNOTHERAPEUTIC APPROACH IN PANCREATIC CANCER 116
Three are better than one: plasminogen receptors as cancer theranostic targets. 115
An integrated proteomic and physiological approach to understand the adhesion mechanism of the probiotic Lactobacillus reuteri Lb2 BM DSM 16143 113
Stromal protein βig-h3 reprogrammes tumour microenvironment in pancreatic cancer 112
Early expression of the fractalkine receptor CX3CR1 in pancreatic carcinogenesis. 110
Generazione della diversità anticorpale 108
Lack of CD4 + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses 108
A new T helper subset producing Interleukin 22 increases in multiplesclerosis patients. 105
CHARACTERIZATION OF AUTOREACTIVE TCR REPERTOIRE IN PATIENTS AFFECTED BYMULTIPLE SCLEROSIS. 105
STAT1 and STAT3 in tumorigenesis: A matter of balance 100
Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia 100
In pancreatic cancer chemotherapy increases anti-tumor responses to tumor associated antigens and potentiates DNA vaccination 100
Antibody and T cell response profiling of pancreatic cancer patients before and after chemotherapy reveals increased recognition of antigens suitable for immunotherapy 97
An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma associated antigen 96
Neutralization of IL-10 And TGF beta 1 rescues T cells from tolerogenic mechanisms induced by HER2 vaccine in cancer patients 93
How do Treg cell function and related cytokines levels change in alemtuzumab treated patients? A 24 months immunological study 92
Antibody and T cell response profiling in pancreatic cancer patients before and after chemotherapy identify tumor associated antigens suitable for immunotherapy 87
Endogenous glutamine decrease is associated with pancreatic cancer progression 85
Identification of Novel Tumor-Associated Antigens in Chronic Lymphocytic Leukemia (CLL) by Serological Proteome Analysis (SERPA) 84
Next generation of cancer immunotherapy calls for combination 83
High Mobility Group Box 1 (hmgb1) Expands CD4+CD25+Foxp3+ T Cells and Increases the Expression of CD39 80
IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF ANTIBODY IMMUNE RESPONSES ELICITED BY SELF ANTIGENS IN CHRONIC LYMPHOCYTIC LEUKEMIA 76
Identification and functional characterization of tumor specific antibody responses in chronic lymphocytic leukemia 76
IDENTIFICATION BY SEROLOGICAL PROTEOME ANALYSIS (SERPA) OF TUMOR-ASSOCIATED ANTIGENS ELICITING ANTIBODY RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) 75
Constitutive expression of the interferon-inducible protein p202 in NIH 3T3 cells affects cell cycle progression. 74
TYPE 1 INTERFERON RECEPTOR (IFNA-R1). EXPRESSING TH17 LYMPHOCYTES ARE INCREASED DURING MS RELAPSES AND ARE SELECTIVELY INTHBITED BY IFNβ 74
Autoantibody signature in human ductal pancreatic adenocarcinoma 74
Human dendritic cells differentiated in hypoxia down modulate antigen uptake and change their chemokine expression profile 74
DNA vaccines coding for chimeric human/rat HER2 as innovative immunotherapeutic tools for the treatment of HER2+ cancer patients 74
Adriamycin-induced proteinuria in nude mice: an immune-system-mediated toxic effect. 72
Iron regulates T-lymphocyte sensitivity to the IFN-gamma/STAT1 signaling pathway in vitro and in vivo. 71
Identification of tumor associated antigens in pancreatic cancer by serological proteome analysis 71
A Mouse To Human Autoantibody Signature in Pancreatic Ductal Adenocarcinoma 71
Serological Proteome Analysis (SERPA) as a tool for the identification of novel tumor antigens in chronic lymphocytic leukemia (CLL) 68
Autoantibodies to the ectoenzyme a enolase, identify a pancreatic adenocarcinoma (PDA)-associated antigen that elicits both CD4 and CD8 T cell response 66
Identification by serological proteome analysis (SERPA) of novel tumor associated antigens in chronic lymphocytic leukemia (CLL) 66
Serological proteome analysis (SERPA) as a tool for the identification of tumor antigens capable of eliciting immune responses in chronic lymphocytic leukemia (CLL) 66
A hypermorphic IkappaBalpha mutation is associated with autosomal dominant anhidrotic ectodermal dysplasia and T cell immunodeficiency. 65
Peptide monofosforilato isolato derivato dall'alfaenolasi umana utile per la diagnosi e il trattamento dell'adenocarcinoma pancreatico, anticorpi diretti contro il suddetto peptide monofosforilato e loro usi 65
DNA vaccination with alpha-enolase effectively prolongs survival in amouse model of human pancreatic cancer. 65
L'IFN-GAMMA HA UN RUOLO FONDAMENTALE NELL'INDUZIONE DI CELLULE LAK, MENTRE NON E' COINVOLTO NELLA STIMOLAZIONE DELL'ATTIVITA' NK 65
THE ACUTE-PHASE PROTEIN HEMOPEXIN IS A NEGATIVE REGULATOR OF TH17 RESPONSE AND EXPERIMENTAL AUTOIMMUNE ENCEPHALOMIELITIS DEVELOPMENT 65
Treg Cell Function and Related Cytokines and Chemokines Changes during Alemtuzumab Treatment: a 24 Months Immunological Study 65
T-Helper (Th)22, a Newly Identified Lymphocyte Subset, Increases 1-3 Months before an MS Relapse and It Is Not Sensitive to IFN beta 64
THE BLOCKADE OF PLASMINOGEN-ALPHA-ENOLASE INTERACTION INHIBITS THE INVASION OF PANCREATIC CANCER CELLS. 63
Ups and downs: the STAT1:STAT3 seesaw of Interferon and gp130 receptor signalling 62
T helper 17 cells expand in multiple sclerosis and are inhibited by interferon-β 62
Identification of tumor associated antigens in pancreatic cancer by serological proteome analysis 62
The balance between IL-17 and IL-22 produced by liver-infiltrating T-helper cells critically controls NASH development in mice 62
Negative cell cycle control of human T cells by beta-galactoside binding protein (beta GBP): induction of programmed cell death in leukaemic cells. 62
Totale 14883
Categoria #
all - tutte 27467
article - articoli 0
book - libri 0
conference - conferenze 8571
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36038


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/20182155 0000 079 121440 9124349475
2018/20192496 833317197 111238 104381 155272552299
2019/20205146 214227384565 374827 531333 522450398321
2020/20214089 412267330273 431353 306236 438316295432
2021/20223837 160167171387 222223 273247 136358777716
2022/20231265 503473114175 00 00 0000
Totale 21789